{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:52:42Z","timestamp":1761663162161},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2013]]},"DOI":"10.2169\/internalmedicine.52.8615","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T22:56:52Z","timestamp":1368572212000},"page":"1101-1105","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic Effects of Lenalidomide on Hemorrhagic Intestinal Myeloma-associated AL Amyloidosis"],"prefix":"10.2169","volume":"52","author":[{"given":"Seiji","family":"Nagano","sequence":"first","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minako","family":"Mori","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiko","family":"Kato","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Ono","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunari","family":"Aoki","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Takiuchi","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Tabata","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soshi","family":"Yanagita","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Departments of Hematology and Clinical Immunology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Kobe City Medical Center General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shinko Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99: 4276-4282, 2002.","DOI":"10.1182\/blood.V99.12.4276"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Durie B, Harousseau J, Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.","DOI":"10.1038\/sj.leu.2404284"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bird J. Guidelines on the diagnosis and management of AL amyloidosis. Br J Haematol 125: 681-700, 2004.","DOI":"10.1111\/j.1365-2141.2004.04970.x"},{"key":"5","unstructured":"5. Tada S, Iida M, Yao T, Kitamoto T, Fujishima M. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 34: 1412-1417, 1993."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chang SS, Lu CL, Tsay SH. Amyloidosis-induced gastrointestinal bleeding in a patient with multiple myeloma. J Clin Gastroenterol 32: 161-163, 2001.","DOI":"10.1097\/00004836-200102000-00015"},{"key":"7","unstructured":"7. Marques M, Sarmento J, Rodrigues S, Guimarães S, Fonseca E, Macedo G. Gastric amyloidosis: unusual cause of upper gastrointestinal hemorrhage. Endoscopy 43: E100-E101, 2011."},{"key":"8","unstructured":"8. Iwahashi N, Tame E, Nagasaka T, Furuta M, Nagashima H, Nimura Y. Massive hemorrhage and pseudo-obstruction of the small intestine caused by primary AL amyloidosis associated with gastric cancer: Report of a case. Surgery Today 34: 871-874, 2004."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rapoport M, Yona R, Kaufman S, Segal M, Kornberg A. Unusual bleeding manifestations of amyloidosis in patients with multiple myeloma. Clin Lab Haematol 16: 349-353, 1994.","DOI":"10.1111\/j.1365-2257.1994.tb00433.x"},{"key":"10","unstructured":"10. Kaiserling E, Krober S. Massive intestinal hemorrhage associated with intestinal amyloidosis. An investigation of underlying pathologic processes. Gen Diagn Pathol 141: 147-154, 1995."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wiernik PH. Amyloid joint disease. Medicine (Baltimore) 51: 465-479, 1972.","DOI":"10.1097\/00005792-197211000-00003"},{"key":"12","unstructured":"12. Pambuccian SE, Horyd ID, Cawte T, Huvos AG. Amyloidoma of bone, a plasma cell\/plasmacytoid neoplasm: Report of three cases and review of the literature. Am J Surg Pathol 21: 179-186, 1997."},{"key":"13","unstructured":"13. Simoens WA, Hauwe LV, Hedent EV, et al. Amyloidoma of the skull base. American Journal of Neuroradiology 21: 1559-1562, 2000."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kumar SK, Dispenzieri A, Lacy MQ, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol 86: 251-255, 2011.","DOI":"10.1002\/ajh.21948"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bowcock SJ, Patrick HE. Lenalidomide to control gastrointestinal bleeding in hereditary haemorrhagic telangiectasia: potential implications for angiodysplasias? Br J Haematol 146: 220-222, 2009.","DOI":"10.1111\/j.1365-2141.2009.07730.x"},{"key":"16","unstructured":"16. Kamalaporn P, Saravanan R, Cirocco M, et al. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series. European Journal of Gastroenterology & Hepatology 21: 1347-1350, 2009."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 29: 1195-1197, 2010.","DOI":"10.1007\/s10067-010-1422-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease. Haematologica 93: 295-298, 2008.","DOI":"10.3324\/haematol.11627"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 90: 201-206, 2011.","DOI":"10.1007\/s00277-010-1062-6"},{"key":"20","unstructured":"20. Reece DE, Hegenbart U, Sanchorawala V, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study. Blood 118: 865-873, 2011."},{"key":"21","unstructured":"21. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109: 492-496, 2007."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sanchorawala V, Finn KT, Fennessey S, et al. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis. Blood 116: 1990-1991, 2010.","DOI":"10.1182\/blood-2010-07-295485"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Palladini G, Russo P, Foli A, et al. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Ann Hematol 91: 89-92, 2012.","DOI":"10.1007\/s00277-011-1244-x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/10\/52_52.8615\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:48:23Z","timestamp":1621446503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/52\/10\/52_52.8615\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.52.8615","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013]]}}}